title: AKT regulation of estrogen receptor beta transcriptional activity in breast cancer.
abstract: Growth factor activation of the phosphatidylinositol 3-kinase (PI3K)-AKT pathway has been shown to activate the estrogen receptor (ER) alpha and to mediate tamoxifen resistance in breast cancer. Here, we investigated the regulation of the transcriptional activity of the newer ER beta by PI3K-AKT signaling. Tissue arrays of breast cancer specimens showed a positive association between the expressions of AKT and ER beta in the clinical setting. Reporter gene assays using pharmacologic and molecular inhibitors of AKT and constitutively active AKT revealed for the first time the ability of AKT to (a) potentiate ER beta activity and (b) target predominantly the activation function-2 (AF2) domain of the receptor, with a requirement for residue K269. Given the importance of coactivators in ER transcriptional activity, we further investigated the possible involvement of steroid receptor coactivator 1 (SRC1) and glucocorticoid receptor-interacting protein 1 (GRIP1) in AKT regulation of ER beta. Mammalian two-hybrid assays revealed that AKT enhanced both SRC1 and GRIP1 recruitment to the ER beta-AF2 domain, and reporter gene analyses revealed that AKT and GRIP1 cooperatively potentiated ER beta-mediated transcription to a level much greater than either factor alone. Investigations into AKT regulation of GRIP with mammalian one-hybrid assays showed that AKT potentiated the activation domains of GRIP1 itself, and in vitro kinase assays revealed that AKT directly phosphorylated GRIP1. The cross-talk between the PI3K-AKT and ER beta pathways, as revealed by the ability of AKT to regulate several components of ER beta-mediated transcription, may represent an important aspect that may influence breast cancer response to endocrine therapy.
authors.affiliation: Center for Bioenvironmental Research, Tulane University, New Orleans, LA, USA.
authors.forename: Bich N
authors.initials: BN
authors.lastname: Duong
authors.forename: Steven
authors.initials: S
authors.lastname: Elliott
authors.forename: Daniel E
authors.initials: DE
authors.lastname: Frigo
authors.forename: Lilia I
authors.initials: LI
authors.lastname: Melnik
authors.forename: Lyndsay
authors.initials: L
authors.lastname: Vanhoy
authors.forename: Suzanne
authors.initials: S
authors.lastname: Tomchuck
authors.forename: Helena P
authors.initials: HP
authors.lastname: Lebeau
authors.forename: Odile
authors.initials: O
authors.lastname: David
authors.forename: Barbara S
authors.initials: BS
authors.lastname: Beckman
authors.forename: Jawed
authors.initials: J
authors.lastname: Alam
authors.forename: Melyssa R
authors.initials: MR
authors.lastname: Bratton
authors.forename: John A
authors.initials: JA
authors.lastname: McLachlan
authors.forename: Matthew E
authors.initials: ME
authors.lastname: Burow
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D002460:Cell Line; D047629:Estrogen Receptor beta / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007668:Kidney; D020411:Oligonucleotide Array Sequence Analysis; D051058:Oncogene Protein v-akt / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D014158:Transcription, Genetic; D014162:Transfection
chemical_list: D047629:Estrogen Receptor beta; D019869:Phosphatidylinositol 3-Kinases; D051058:Oncogene Protein v-akt